A number of studies reported significant benefits in individuals with type 2 diabetes, with respect to reversal of liver steatosis and reduction in plasma aminotransferase levels, following treatment with the SGLT2 inhibitors empagliflozin [94, 95], dapagliflozin [96], canagliflozin [97, 98], luseogliflozin [99, 100], ipragliflozin [101, 102] and ertugliflozin [103] (see Table 5 for further information and references). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.